Protocol Ledger

NCT06527144 · Phase II · COMPLETED

A Clinical Trial of TQC3721 Suspension for Inhalation in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease

Interventional Phase II clinical trial protocol NCT06527144 sponsored by Chia Tai Tianqing Pharmaceutical Group Co in Respiratory and Pulmonary, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-09-14 Enrollment: 240 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06527144
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)240 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)2 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06527144
Protocol FieldVerified Registry Value
NCT IdentifierNCT06527144
Consolidated Lead SponsorChia Tai Tianqing Pharmaceutical Group Co
Therapeutic Condition CohortRespiratory and Pulmonary
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment240 participants (ACTUAL)
Registered Start Date2024-09-14
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06527144
Hospital Research SiteLocationSite Profile
The First Hospital of Lanzhou UniversityLanzhou, ChinaOpen Hospital Dossier ->
The First Affiliated Hospital of Guangzhou Medical UniversityGuangzhou, ChinaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Respiratory and Pulmonary Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI